Literature DB >> 31254558

Hybrid drug nanocrystals.

Yi Lu1, Yongjiu Lv2, Tonglei Li3.   

Abstract

Nanocrystals show promise to deliver poorly water-soluble drugs to yield systemic exposure. However, our knowledge regarding the in vivo fate of nanocrystals is in its infancy, as nanocrystallization is simply viewed as an approach to enhance the dissolution of drug crystals. The dying crystal phenomenon inspired the development of hybrid nanocrystals by physically embedding fluorophores into the crystal lattice. This approach achieved concurrent therapy and bioimaging and is well-established to study pharmacokinetics and nanocrystal dissolution in vivo. Nanocrystals also offer the advantage of long-term durability in the body for interacting with biological tissues and cells. This review introduces the hybrid nanocrystal technique, including the theoretical concepts, preparation, and applications. We also discuss the latest development in self-discriminative hybrid nanocrystals utilizing environment-responsive probes. This review will stimulate further development and application of nanocrystal-based drug delivery systems for theranostic strategies.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ACQ; AIE; FRET; Fate; Hybrid nanocrystals; In vivo; Intracellular

Mesh:

Substances:

Year:  2019        PMID: 31254558     DOI: 10.1016/j.addr.2019.06.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  9 in total

Review 1.  Nanocrystals for Improving Oral Bioavailability of Drugs: Intestinal Transport Mechanisms and Influencing Factors.

Authors:  Zonghua Tian; Yaping Mai; Tingting Meng; Shijie Ma; Guojing Gou; Jianhong Yang
Journal:  AAPS PharmSciTech       Date:  2021-06-14       Impact factor: 3.246

2.  The long-circulating effect of pegylated nanoparticles revisited via simultaneous monitoring of both the drug payloads and nanocarriers.

Authors:  Wufa Fan; Haixia Peng; Zhou Yu; Luting Wang; Haisheng He; Yuhua Ma; Jianping Qi; Yi Lu; Wei Wu
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 14.903

Review 3.  Drug Nanocrystals for Active Tumor-Targeted Drug Delivery.

Authors:  Linwei Lu; Qianzhu Xu; Jun Wang; Sunyi Wu; Zimiao Luo; Weiyue Lu
Journal:  Pharmaceutics       Date:  2022-04-06       Impact factor: 6.525

Review 4.  Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment.

Authors:  Fei Qu; Rui Geng; Yijing Liu; Jintao Zhu
Journal:  Theranostics       Date:  2022-04-11       Impact factor: 11.600

Review 5.  Advanced modification of drug nanocrystals by using novel fabrication and downstream approaches for tailor-made drug delivery.

Authors:  Tao Liu; Xinxin Yu; Haipeng Yin; Jan P Möschwitzer
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

6.  Oral delivery of carrier-free dual-drug nanocrystal self-assembled microspheres improved NAD+ bioavailability and attenuated cardiac ischemia/reperfusion injury in mice.

Authors:  Hongfei Nie; Yarong Zhang; Haiyang Yu; Hong Xiao; Tao Li; Qian Yang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

7.  Ionic co-aggregates (ICAs) based oral drug delivery: Solubilization and permeability improvement.

Authors:  Xianzi Zheng; Zhezheng Fang; Weizi Huang; Jianping Qi; Xiaochun Dong; Weili Zhao; Wei Wu; Yi Lu
Journal:  Acta Pharm Sin B       Date:  2022-04-26       Impact factor: 14.903

8.  Mechanism and Improved Dissolution of Glycyrrhetinic Acid Solid Dispersion by Alkalizers.

Authors:  Luning Dong; Yaping Mai; Qiang Liu; Wannian Zhang; Jianhong Yang
Journal:  Pharmaceutics       Date:  2020-01-20       Impact factor: 6.321

9.  Nanogels with High Loading of Anesthetic Nanocrystals for Extended Duration of Sciatic Nerve Block.

Authors:  Teresa Alejo; Laura Uson; Guillermo Landa; Martin Prieto; Cristina Yus Argón; Sara Garcia-Salinas; Ricardo de Miguel; Ana Rodríguez-Largo; Silvia Irusta; Victor Sebastian; Gracia Mendoza; Manuel Arruebo
Journal:  ACS Appl Mater Interfaces       Date:  2021-04-06       Impact factor: 9.229

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.